

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5032538

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MD ANDERSON CANCER CENTER	06/28/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
<b>Street Address:</b>	NIH, 6705 ROCKLEDGE DRIVE, SUITE 130
<b>City:</b>	BETHESDA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20892-7980
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	13286887
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(713)563-9568
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7137459884
<b>Email:</b>	dortiz3@mdanderson.org
<b>Correspondent Name:</b>	DANIEL ORTIZ
<b>Address Line 1:</b>	7007 BERTNER AVE, 1MC9.2123
<b>Address Line 2:</b>	UNIT 1669
<b>Address Line 4:</b>	HOUSTON, TEXAS 77030-4009
<b>ATTORNEY DOCKET NUMBER:</b>	MDA00-025USDIV
<b>NAME OF SUBMITTER:</b>	DANIEL ORTIZ
<b>SIGNATURE:</b>	/Daniel Ortiz/
<b>DATE SIGNED:</b>	07/02/2018
<b>Total Attachments: 1</b>	
source=EPAS_00-025USDIV_Signed#page1.tif	

# License to the United States Government

(Sign and submit this executed document to the United States Patent and Trademark Office --  
Electronic Patent Assignment System (EPAS) <http://epas.uspto.gov>)

Executive Order 9424: Government Support License (Government Support Clause)

Invention title: Human And Mouse Targeting Peptides Identified By Phase Display

Inventor(s): Renata Pasqualini; Wadih Arap

U.S. Filing/Issue Date: 11/01/2011

Patent or Application Serial No: 13/286,887

Grant/Contract Number(s): CA078512, CA082713, CA082976, CA090810, CA090270, DAMD17-98-1-8581, DAMD17-98-1-8041

Foreign Applications filed/intended in (countries): \_\_\_\_\_

The invention identified above is a subject invention under 35 U.S.C. 200, et seq., and the Standard Patent Rights Clause at 37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12 (if applicable) which are included among the terms of the above identified grant or contract award from the United States Government. This document is confirmatory of:

1. As required by 37 CFR 401.14 (f) (2) and Executive Order 9424:


This invention was made with government support under Grant/Contract Number(s) CA078512, CA082713, CA082976, CA090810, CA090270 awarded by the National Institutes of Health and Grant/Contract Number(s) DAMD17-98-1-8581 and DAMD17-98-1-8041 awarded by the U.S. Department of the Army. The government has certain rights in the invention.

2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 29 day of June 2018.

By: Andrew P. Dennis, PhD  
Institutional Business Official Printed Name and Title

  
Signature

Title Managing Director, Office of Technology Commercialization

For MD Anderson Cancer Center  
Grantee/Contractor Organization

At OFFICE OF TECHNOLOGY COMMERCIALIZATION 7007 Bertner Ave., 1MC9.2125, Houston, Texas 77030-3907  
Business Address